Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(3.03)
# 2,675
Out of 5,133 analysts
112
Total ratings
42.42%
Success rate
1.68%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GHRS GH Research | Maintains: Buy | $35 → $39 | $15.84 | +146.21% | 5 | Jan 6, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $28 → $36 | $30.58 | +17.72% | 5 | Jan 5, 2026 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $25 | $14.87 | +68.12% | 2 | Nov 7, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $8.92 | +169.06% | 7 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $132.26 | +24.00% | 17 | Oct 29, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.67 | +281.47% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $3.12 | +444.87% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $5.10 | +841.18% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $7.37 | +103.53% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $7.54 | +258.09% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $265 → $220 | $178.30 | +23.39% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $4.02 | +198.51% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $2.05 | +3,802.44% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $26.46 | +24.72% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $10.97 | +1,267.37% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $32.47 | - | 2 | Jan 31, 2017 |
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $15.84
Upside: +146.21%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $28 → $36
Current: $30.58
Upside: +17.72%
Mind Medicine (MindMed)
Nov 7, 2025
Maintains: Buy
Price Target: $16 → $25
Current: $14.87
Upside: +68.12%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $8.92
Upside: +169.06%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $132.26
Upside: +24.00%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.67
Upside: +281.47%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $3.12
Upside: +444.87%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $5.10
Upside: +841.18%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $7.37
Upside: +103.53%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $7.54
Upside: +258.09%
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $178.30
Upside: +23.39%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.02
Upside: +198.51%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.05
Upside: +3,802.44%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $26.46
Upside: +24.72%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $10.97
Upside: +1,267.37%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $32.47
Upside: -